United States

People: Sarepta Therapeutics Inc (SRPT.O)

SRPT.O on Nasdaq

20 Aug 2019
Change (% chg)

$-18.24 (-15.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Ingram, Douglas 

Mr. Douglas S. Ingram serves as President, Chief Executive Officer, Director of the company. Mr. Ingram has served as our President, Chief Executive Officer and a member of our Board since June 2017. Prior to his appointment, from December 2015 until November 2016, he served as the Chief Executive Officer and President and a Director of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company. Prior to joining Chase Pharmaceuticals, Mr. Ingram served as the President of Allergan, Inc., a pharmaceutical company, from July 2013 until it was acquired by Actavis in early 2015. At Allergan, he also served as President, Europe, Africa and Middle East from August 2010 to June 2013, and Executive Vice President, Chief Administrative Officer, and Secretary from October 2006 to July 2010, where he led Allergan’s Global Legal Affairs, Compliance, Internal Audit and Internal Controls, Human Resources, Regulatory Affairs and Safety, and Global Corporate Affairs and Public Relations departments. Mr. Ingram also served as General Counsel of Allergan from January 2001 to June 2009 and as Secretary and Chief Ethics Officer from July 2001 to July 2010. With the acquisition of Allergan by Actavis, Mr. Ingram consulted as a special advisor to the Chief Executive Officer of Actavis. Mr. Ingram serves as a director of Pacific Mutual Holding Company, a parent company for subsidiaries engaged in a variety of insurance, financial services and other investment-related businesses, where he is a member of the Compensation Committee, the Governance and Nominating Committee, and the Member Interests Committee. Mr. Ingram received his J.D. from the University of Arizona and his Bachelor of Science degree from Arizona State University.

Basic Compensation

Total Annual Compensation, USD 1,428,050
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 5,822
Fiscal Year Total, USD 1,433,870

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

M. Kathleen Behrens


Douglas Ingram


Sandesh Mahatme


David Howton


Alexander Cumbo


Gilmore O'Neill

As Of  30 Dec 2018